Company intelligence / Profile preview
Suzhou Nuojiebei Biotechnology
Suzhou, Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Suzhou Nuojiebei Biotechnology is a clinical-stage biotech company developing AAV-based gene therapies for rare genetic and ophthalmic diseases. Its lead programs are in Phase 2 for Bietti crystalline dystrophy, wet age-related macular degeneration, and phenylketonuria. The hemophilia A program NGGT‑003 is in early Phase 1 with positive preliminary results showing shorter bleeding time in patients.
- Therapeutic areas
- OphthalmologyHematologyMetabolic DisordersImmunology
- Modalities
- AAV based gene therapyFusion proteinBiological products
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Suzhou Nuojiebei Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Nuojiebei Biotechnology.